论文部分内容阅读
目的:评价重组人血小板生成素注射液在不同原发病所致血小板减低患者中的疗效。方法:采用回顾性病例对照研究方法,选取某院2013年至2016年使用重组人血小板生成素注射液患者的病例资料,根据血小板减低原因将患者分为血液病组、重症感染组、肝移植组。记录用药前后血小板计数,血小板恢复正常时间,血制品输注量等各项指标。采用SPSS17.0对数据进行统计学方法处理,计数资料采用χ2检验,计量资料采用T检验,评价各组间的疗效。结果:皮下注射重组人血小板生成素注射液各组患者血小板计数明显高于用药前(P<0.05),各组间血小板增值比较显示重症感染组与肝移植组血小板增值无显著差异(P>0.05),而血液病组血小板计数升高明显低于重症感染组和肝移植组(P<0.05);用药后血液病组PLT计数<50×109/L持续时间明显高于重症感染组和肝移植组;各组疗效比较血液病组优效比例明显低于重症感染组和肝移植组(P<0.05)。3组血小板输注量比较,重症感染组和肝移植组显著低于血液病组(P<0.05)。结论:皮下注射常规剂量重组人血小板生成素注射液使患者血小板计数明显上升,恢复加快,血小板输注量明显减少,对重症感染和肝移植患者尤为显著。
Objective: To evaluate the efficacy of recombinant human thrombopoietin injection in patients with thrombocytopenia caused by different primary diseases. Methods: A retrospective case-control study was conducted to select the patients using recombinant human thrombopoietin injection from 2013 to 2016 in our hospital. According to the causes of thrombocytopenia, the patients were divided into hematological disease group, severe infection group and liver transplantation group . Record before and after treatment of platelet count, platelet recovery time, the amount of blood transfusion and other indicators. SPSS17.0 was used to process the data statistically. Chi-square test was used to count data and T-test was used to evaluate the curative effect of each group. Results: The platelet count in each group of subcutaneous injection of recombinant human thrombopoietin was significantly higher than that before treatment (P <0.05). The comparison of thrombocytopenia between groups showed no significant difference of platelet proliferation between severe infection group and liver transplantation group (P> 0.05 ), While the hematological group had a significantly higher platelet count than the severe infection group and the liver transplantation group (P <0.05). The duration of PLT count <50 × 109 / L in hematological disease group was significantly higher than that in severe infection group and liver transplantation group Group; the curative effect of each group was significantly lower than that of severe infection group and liver transplantation group (P <0.05). The platelet transfusion volume in the three groups was significantly lower than that in the hematological group (P <0.05) in the severe infection group and the liver transplantation group. Conclusion: The subcutaneous injection of recombinant human thrombopoietin injection significantly increases the platelet count, accelerates the recovery and decreases the platelet transfusion, especially for patients with severe infection and liver transplantation.